ETFs Roche Holding AG

ROG

CH0012032048

Name	Weight	AuM	1st Jan change
LYXOR DJ SWITZERLAND TITANS 30 (DR) UCITS ETF- CHF	9.03%	121 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	8.46%	21 M€	+4.14%	-
FIRST TRUST INTERNATIONAL CAPITAL STRENGTH ETF - CAD	2.47%	7 M€	+12.99%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	1.77%	32 M€	+14.66%	-
FRANKLIN LIBERTYQ EUROPEAN EQUITY UCITS ETF - EUR	1.75%	0 M€	-.--%	-
HANETF SATURNA SUSTAINABLE ESG EQUITY HANZERO UCITS ETF - USD	1.7%	0 M€	-.--%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	1.69%	0 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS MINIMUM VOLATILITY BLUE UCITS ETF B - USD	1.53%	0 M€	-.--%	-
INDEXIQ FACTORS SUSTAINABLE EUROPE EQUITY UCITS ETF - EUR	1.4%	154 M€	+13.47%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	1.37%	9 M€	+15.41%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.85%	33,076 M€	+11.29%	-
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.64%	1,022 M€	+20.44%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.53%	0 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB - UCITS ETF DR (C) - USD	0.51%	0 M€	-.--%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.5%	0 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.49%	331 M€	+0.46%	-
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.48%	0 M€	-.--%	-

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

07-24 - Q2 2025 Earnings Release

More about the company